To the Editor: In the WENBIT study, Dr Ebbing and colleagues1 reported a significant 30% reduction in baseline homocysteine levels (from 10.8 μmol/L to 7.6 μmol/L) in the active treatment group (folic acid and vitamin B12) after 1 year of treatment. However, both mean baseline and final homocysteine levels were within the normal range (<15 μmol/L), meaning that homocysteine was reduced to a lower value from a higher but still normal value.
Lowering Homocysteine With B Vitamins in Patients With Coronary Artery Disease. JAMA. 2008;300(24):2852-2854. doi:10.1001/jama.2008.836